PolyPid's drug-delivery tech combines polymers and lipids

PolyPid, an Israeli drug-delivery company, has introduced a new family of drug carriers based on a melding of two drug delivery systems: polymers and lipid-based systems. The PolyPid carrier carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs.

The company's technology ensnares a large variety of one or more biologically active molecules and releases them at a pre-programmed rate for up to several months. PolyPid produces a product called BonyPid, a biodegradable bone void filler. After BonyPid releases its coating, over time, the bone void filler scaffold remains and supports bone recovery. This way, according to the company, physicians can "obtain the benefits of conventional bone void filler combined with an effective local drug delivery system."

"Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopedics, urology, periodontal, anti-cancer/anti-fungal treatments and surgical accessories," PolyPid CTO Noam Emanuel said in a news release.

- read PolyPid's release
- and a brief report on PBR

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.